Methods for Mediation Analysis with High-Dimensional DNA Methylation Data: Possible Choices and Comparison

4 Dylan Clark-Boucher¹, Xiang Zhou², Jiacong Du², Yongmei Liu³, Belinda L
 5 Needham⁴, Jennifer A Smith^{4,5}, Bhramar Mukherjee^{2,4}

7	¹ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA
8	² Department of Biostatistics, University of Michigan, Ann Arbor, MI
9	³ Department of Medicine, Divisions of Cardiology and Neurology, Duke University Medical
10	Center, Durham, NC
11	⁴ Department of Epidemiology, University of Michigan, Ann Arbor, MI

- ⁵Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI
- 13

1

2 3

6

14 Abstract

Epigenetic researchers often evaluate DNA methylation as a mediator between social/environmental 15 exposures and disease, but modern statistical methods for jointly evaluating many mediators have not 16 been widely adopted. We compare seven methods for high-dimensional mediation analysis with 17 18 continuous outcomes through both diverse simulations and analysis of DNAm data from a large national cohort in the United States, while providing an R package for their implementation. Among the 19 considered choices, the best-performing methods for detecting active mediators in simulations are the 20 21 Bayesian sparse linear mixed model by Song et al. (2020) and high-dimensional mediation analysis by Gao et al. (2019); while the superior methods for estimating the global mediation effect are high-22 23 dimensional linear mediation analysis by Zhou et al. (2021) and principal component mediation analysis by Huang and Pan (2016). We provide guidelines for epigenetic researchers on choosing the best method 24

25 26

27 Introduction

28 In this study, we review and evaluate the available methods for performing mediation analysis when the

29 mediators are high-dimensional DNA methylation (DNAm) measurements. DNAm is an epigenomic

- 30 mechanism describing when a methyl group binds to the DNA, which occurs predominantly at cytosine-
- 31 guanine dinucleotides, called "CpG sites." DNAm has an important role in regulating gene expression
- across the entire genome, and is particularly impactful at CpG sites in the promoter regions of genes,

33 where it can inhibit the binding of enzymes needed for transcription¹.

in practice and offer suggestions for future methodological development.

- Recent advancements in technology have made it possible to collect DNAm data on a massive
- scale². Indeed, microarray technologies have enabled the measurement of over 850,000 CpG sites
- 36 simultaneously², encouraging broad research on DNAm in the etiology of disease; and studies taking
- advantage of these tools have identified DNAm as a risk factor in obesity^{3,4}, type II diabetes⁵ and
- $cardiovascular conditions^{6,7}$. At the same time, however, DNAm has also been linked to exposures such as
- $diet^8$, smoking⁹, alcohol¹⁰, air pollution¹¹, and socioeconomic status (SES)^{12,13}, which has prompted
- 40 research on whether the effects of these exposures on health outcomes could be transferred by changes in

- 41 DNAm. Effect transmission of this nature is called *mediation*, and it has become popular in epigenomic
- research to treat DNAm as a high-dimensional mediator between environmental exposures and human
 disease¹⁴.
- 44 As an example of such an analysis, our previous work 15,16 examined the association between low
- 45 SES and glycated hemoglobin (HbA1c) in the Multi-Ethnic Study of Atherosclerosis (MESA), a United
- 46 States population-based longitudinal study¹⁷. Indicators of SES, such as education level, are strong
- 47 predictors of type II diabetes¹⁸, while HbA1c is an important risk factor of cardiovascular disease and a
- 48 critical biomarker in type II diabetes diagnosis $^{19-21}$. Since education level is also associated with
- 49 DNAm 12,13,22 , and DNAm itself with HbA1c level²³, we hypothesized that if low education results in
- 50 greater HbA1c, part of that effect could be mediated by DNAm (Fig. 1). In the current study, we revisit
- 51 this hypothesis for the purpose of illustration. Our sample from MESA has 963 individuals and includes
- 52 DNAm measurements at 402,339 CpG sites, none of which we know for certain are related to education 53 or HbA1c in advance.
- 54



55

Fig. 1. Proposed causal mechanism in which the effect of low education on HbA1c is mediated by DNAm 57

The standard statistical tool for addressing such a hypothesis is mediation analysis. Formally, 58 mediation is when an exposure, say A, affects an outcome, Y, in part through its effect on a single 59 60 mediating variable M. When M is a mediator of the A to Y association, the total effect of A on Y has two components: an *indirect effect*, from A affecting M and M affecting Y, and a *direct effect*, from A affecting 61 62 Y independently of M. In the "traditional mediation analysis" approach proposed by Baron and Kenny 63 (1986), the associations from this mechanism could be measured by fitting a few regression models: one for the effect of A on M (the mediator model), one for the effects of A and M on Y (the outcome model), 64 and sometimes a third model for the total effect of A on Y, M ignored^{24–26}. The more recently developed 65 "causal mediation analysis," based on the counterfactual approach^{27,28}, has established conditions under 66 which the parameters of these models can be interpreted as causal effects²⁹. The causal approach is more 67 flexible when Y or M are binary and when there is A-M interaction in the outcome model³⁰. 68

69 70

While standard examples of mediation consider only one exposure, one mediator, and one 71 outcome^{31,32}, there has been growing interest in methods for mediation that can handle many potential 72 mediators at once. Epigenetic studies have felt this need especially, as DNAm is usually measured at 73 74 several hundred thousand CpG sites with little prior knowledge of their importance. In settings such as 75 this, a naïve strategy would be to evaluate the potential mediators one at a time, each with their own pair of models; but if the mediators are correlated this approach is inefficient, and the resulting estimates are 76 77 potentially biased due to confounding from the excluded co-mediators³¹. Instead, so that we leverage 78 these correlations rather than ignore them, the preferred approach is to assess the mediators jointly, in a 79 single multivariable model. Although several methods for fitting such a model have been presented in the 80 literature, none of them are widely used in analyzing DNAm data, a sign that epigenetic research is still catching up to recent developments in mediation analysis with high-dimensional mediators. 81

82 Our study aims to bridge this gap and guide researchers in epigenetics to use state of the art methods for mediation analysis with high-dimensional mediators. Despite the recent methodological 83 developments, there are no clear-cut standards for which methods should be applied in which 84 circumstances, making it difficult to select the best-suited method for an analysis in advance. While our 85 86 prior research examined methods for large scale single-mediator hypotheses³¹, there is no such work for methods that can incorporate many potential mediators at once. Our study addresses this question first 87 with an extensive simulation study, directly comparing the performance of sevesn different methods for 88 89 mediation with high-dimensional mediators across a spectrum of settings. Along with metrics related to 90 identification of key mediators and estimation of mediation effect, we include a computation time 91 comparison to evaluate the scalability of the methods to large datasets. Next, to assess the utility of these methods on real data, we apply the same seven methods-plus two additional methods adapted from 92 them—on the data from MESA to evaluate the mediating role of DNAm in the association between low 93 94 education level and HbA1c. Our study is the first to address this critical gap in the epigenetic mediation 95 literature, both by providing clarity on the methods available and by assessing their strengths and 96 weaknesses under different settings. Moreover, although the analysis is centered around DNAm, the 97 methods we deploy are not specific to epigenetics, and our results and guidelines should be similarly 98 useful for researchers studying high-dimensional mediation problems in other fields. We include, supplementary to our study, an R package for implementing the methods, called "hdmed," so that 99 researchers have access to a centralized resource they can draw from in their own high-dimensional 100 mediation analyses. 101

102

103 Notations and General Framework

Before proceeding, it will be useful to provide an overview of the relevant mediation model and to summarize the types of methods which have become available. To begin, suppose we have a dataset of *n* individuals: an exposure A_i , a continuous outcome Y_i , and continuous mediators M_i measured for the i^{th} person, *i* varying from 1 to *n*. We write M_i in bold to indicate its status as a vector—in this case, a set of *p* mediators $M_i^{(j)}$, *j* varying from 1 to *p*. Let C_i be a vector of *q* covariates. When *p* is greater than 1, we can use the regression models

$$E[Y_i|A_i, \boldsymbol{M}_i, \boldsymbol{C}_i] = \beta_a A_i + \boldsymbol{\beta}_m^T \boldsymbol{M}_i + \boldsymbol{\beta}_c^T \boldsymbol{C}_i$$
(1)

111 and

110

112

$$E[\boldsymbol{M}_i|A_i, \boldsymbol{C}_i] = \boldsymbol{\alpha}_{\boldsymbol{a}}A_i + \boldsymbol{\alpha}_{\boldsymbol{c}}\boldsymbol{C}_i \tag{2}$$

to estimate the mediating role of M_i in the causal pathway between the exposure and outcome³³. Model (1) is the outcome model and model (2) is the mediator model. In model (1), β_m is a *p*-vector in which the

115 j^{th} component, $(\beta_m)_j$, is the linear association of j^{th} mediator with Y_i adjusting for the other variables; while 116 β_a is the association between A_i and Y_i adjusting for mediators and covariates. In model (2), α_a is a *p*-117 vector of the associations between the exposure and each mediator, $(\alpha_a)_j$; and α_c is a matrix with the 118 mediator-covariate associations. Also note that in model (1), we have assumed there is no interaction

119 between A_i and M_i , which is beyond the scope of our present study.

120 The parameters of these models underly the causal effects of interest. Under certain assumptions^{27,33}, the direct effect of A_i on Y_i is β_a , the global indirect effect (or global mediation effect) of 121 A_i on Y_i through M_i is $\alpha_a^T \beta_m$, and the total effect of A_i on Y_i is $\beta_a + \alpha_a^T \beta_m$. Another quantity of interest is 122 the proportion mediated, defined as the ratio of the global indirect effect to the total effect, which 123 124 measures the degree to which the A_i to Y_i pathway is mediated by M_i . We may also seek to measure the product terms $(\alpha_a)_i(\beta_m)_i$, which measure the contribution of the jth mediator to the global indirect effect, 125 since summing these for *j* from 1 to *p* yields $\alpha_a^T \beta_m$. However, we emphasize that $(\alpha_a)_i (\beta_m)_i$ cannot be 126 interpreted as a causal effect through the i^{th} mediator on its own, since we have made no assumptions 127 128 about the causal ordering of the mediators and can only formally treat them as a joint system. Instead, we call $(\alpha_n)_i(\beta_m)_i$ the mediation contribution, and describe the i^{th} mediator as active if its contribution is not 129

130 zero.

131 If the potential mediators are uncorrelated, conditional on the exposure and covariates, or if p is 132 reasonably small relative to n, then it is trivial to fit the above models using linear regression. However, if the mediators are correlated and p is large, the estimates from model (1) may have extremely high 133 variance; and if p is so large as to exceed n, the linear regression model cannot even be fitted. These 134 concerns are relevant to us because DNAm measurements tend to be correlated, while the number of sites 135 that we have measurements on exceeds the number of samples. Addressing these issues has been a focus 136 of the mediation literature, with authors using penalized regression^{34–38}, dimension reduction^{39–41}, 137 Bayesian inference^{15,42}, and latent variables⁴³ to make the outcome model statistically tractable. 138

We provide a graphical depiction of eleven available methods in Fig. 2, dividing them into three 139 140 different groups. Each method is described in greater detail in the Methods section and up to nine of them are included in the analysis. In the first group, we consider methods that fit the above pair of models 141 explicitly, allowing one to estimate $\alpha_a^T \beta_m$, the global indirect effect, simply by summing the estimated 142 143 mediation contributions. These include high-dimensional mediation analysis (HIMA) by Zhang et al. 2016³⁴, high-dimensional mediation analysis (HDMA) by Gao et al. 2019³⁵, mediation analysis via fixed 144 effect model (MedFix) by Zhang 2019³⁶, pathway least absolute shrinkage operator (pathway LASSO) by 145 Zhao and Luo 2022³⁷, the Bayesian sparse linear mixed model (BSLMM) by Song et al. 2020¹⁵, and the 146 Gaussian mixture model (GMM) by Song et al. 2021⁴². In the second group, we consider methods that 147 can estimate $\alpha_a^T \beta_m$ "directly"; in other words, without needing to fit the original pair of models explicitly. 148 These have the drawback of being unable to identify specific active mediators because they do not 149 provide estimates of the mediation contributions. They include principal component mediation analysis 150 (PCMA) by Huang and Pan 2016³⁹, sparse principal component mediation analysis (SPCMA) by Zhao et 151 al. 2020⁴⁰, and high-dimensional linear mediation analysis (HILMA) by Zhou et al. 2021³⁸. Last, in the 152 third group, we consider methods that make no attempt to estimate the mediation effects as originally 153 proposed, but instead reconceptualize the mediation framework with newly-defined parameters based on 154 latent variables. This group includes the methods high-dimensional multivariate mediation analysis 155 (HDMM) by Chén et al. 2018⁴¹ and latent variable mediation analysis (LVMA) by Derkach et al. 2021⁴³. 156 Within this comparative structure, we evaluate methods from all three groups, identifying their strengths 157 and weaknesses across a wide range of simulation settings and analysis of DNAm data from MESA. 158



162 Fig. 2. Methods for mediation analysis with high-dimensional DNAm data. Figure describes eleven methods for

163 mediation analysis that can be applied to high-dimensional DNA methylation data, each of which is described in 164 greater detail in the Methods section. Seven of these methods are included in the simulation study and nine in the

We begin by comparing the performance of the methods using simulations, where we know and

observed DNAm data analysis with MESA. Group 1 methods fit the outcome model explicitly using penalized
 regression or Bayesian regression; Group 2 methods obtain the global mediation effect without fitting the original

167 outcome model explicitly; and Group 3 methods measure mediation through latent variables.

168

171

169 **Results**

170 Simulation Results

can control the true values of the parameters. On simulated data with 2,000 (potential) mediators and 172 173 either 1,000 or 2,500 observations, we consider (1) a baseline setting, where the mediators are moderately correlated and their signals are sparse; (2) a high-correlation setting, where the correlations between 174 mediators are enhanced compared to (1); and (3) a non-sparse setting, where every mediator has at least 175 some mediation signal but some of the signals are systematically larger. In Settings (1) and (2), 60 176 177 random mediators have $(\alpha_a)_i$ only sampled from a Normal(0,1), 60 have $(\beta_m)_i$ only sampled from a Normal(0,1), and 20 have both, with the remaining entries of α_a and β_m fixed at zero. In Setting (3), we 178 use a similar scheme, but sample the previously zero $(\alpha_a)_i$ and $(b_m)_i$ from a Normal $(0,0.2^2)$. Our 179 180 simulations also vary the strength of the signals within each of these settings by changing the proportion of variance that is explained by the associations. We do so by changing PVEA, the proportion of variance 181 in each mediator that can be explained by A, among those mediators that are affected by A; PVE_{IE} , the 182 proportion of variance of Y that is explained by the total mediation effect; and PVE_{DE}, the proportion of 183 variance of Y that is explained by the direct effect of A on Y. Results for varying PVE_{IE} are presented here 184 while results for varying PVE_{DE} and PVE_A are included in the supplement (Supplementary Figs 1-4). In 185 addition to the high-dimensional mediation methods, we include a one-at-a-time method⁴⁴ in which the 186 mediators are assessed individually using linear regression. We evaluate the methods by their true 187 positive rate (TPR) for detecting active mediators, their mean squared error (MSE) for estimating the 188 contributions of active and inactive mediators, and their percent relative bias for estimating the global 189 indirect effect. See Methods for more details. 190

191

192 True positive rate

Fig. 3 compares the TPR detecting active mediators of the Group 1 methods and the one-at-a-time method. The value shown is the mean TPR over 100 simulated datasets and a 95% empirical confidence interval (CI). On each dataset and for each method, thresholding was used to keep the false discovery rate (FDR) below 10%. For the non-sparse setting, we show the TPR for detecting mediators whose (α_a)_j and (β_m)_j were both sampled from Normal(0,1) rather than Normal(0,0.2²). We include the Group 1 methods HIMA, HDMA, MedFix, pathway LASSO, and BSLMM. We focus on TPR but not false positive rate (FPR) because the FDR correction was highly conservative, the mean FPR ranging from 0 to 5.1x10⁻⁴

across all settings and methods.

For a sample size of 2,500 and a PVE_{IE} of 0.10, the most powerful method in the baseline setting was BSLMM (mean TPR: 0.45; CI: 0.25 - 0.63), whose average TPR was 40% higher than that of the second-best method, HDMA. BLSMM also performed best when PVE_{IE} was 0.05 (mean TPR: 0.25; CI: 0.02 - 0.48), but to a lesser degree, outperforming HDMA by only 13%. BSLMM remained the best

205 method, and HDMA the second best, no matter the signal strength or the degree of correlations, but

 $206 \quad \ \text{performed poorly when the signals were non-sparse. In the setting with 1,000 observations, PVE_{IE} set to$

207 0.05, and non-sparse signals, the best-performing method was HIMA (mean TPR: 0.09; CI: 0.05 - 0.10),

its average TPR 3.3 times higher than that of BSLMM, which performed worst.

209



Fig. 3. True positive rate for detecting mediation signals at a false discovery rate of 10%. Value shown is the 210 211 mean TPR across 100 simulated data replicates, with intervals representing the inner 95% range. In the baseline and 212 high-correlation-among-mediators settings, TPR is for distinguishing mediators which contribute to the global 213 mediation effect from those which do not, whereas in the non-sparse setting, TPR is for distinguishing mediators 214 whose contributions were sampled from a high-variance distribution from those whose contributions were sampled 215 from a low-variance distribution. False discovery proportion was capped below 10% by a proper choice of the p-216 value threshold (one-at-a-time, HIMA, HDMA, MedFix), posterior inclusion probability threshold (BSLMM), or 217 method tuning parameter (pathway LASSO).

218

219 Estimation of contributions of active mediators

- 220 Next, we assess the MSE of the methods for estimating mediation contributions, relative to the one-at-a-
- time approach. In Fig. 4, we show the relative MSE (rMSE) for estimating mediation contributions
- among the mediators that were either active (in the baseline and high-correlation settings) or had $(\alpha_a)_j$ or
- 223 $(\beta_m)_j$ sampled from the larger-variance distribution (in the non-sparse setting). In the baseline setting with
- 224 2,500 observations, the best-performing method when the mediation signal was strong was BSLMM,
- whose mean rMSE of 0.59 (CI: 0.13 1.51) was 24% lower than that of HDMA, the second-best method.
- However, when the PVE_{IE} was reduced to 0.05 or the sample size reduced to 1,000, the best-performing
- 227 method was either HDMA or MedFix, with MedFix (mean rMSE: 0.79; CI: 0.31 1.53) performing 61%

228 better than BSLMM after reducing both. Similar trends were observed for the high-correlation and non-

sparse settings.





Fig. 4. MSE in estimating mediation contributions of active mediators, relative to one-at-a-time method. Yaxis is on a log₁₀ scale. Value shown is the mean of the relative mean-squared error for estimating mediation
contributions among active mediators (relative to the one-at-a-time approach) across 100 simulated data replicates,
with intervals representing the inner 95% range. For baseline and high-correlation-between-mediators settings,
active mediators which contribute to the global mediation effect, whereas in the non-sparse setting, active mediators
are those whose contributions were sampled from a distribution with large variance instead of small.

237

238 Estimation of contributions of inactive mediators

239 Figure 5 shows the rMSE among the mediators that either were not active (in the baseline and 240 high-correlation settings) or had $(\alpha_a)_i$ or $(\beta_m)_i$ sampled from the smaller-variance distribution (in the nonsparse setting). We exclude pathway LASSO from Fig. 4 because for the baseline and high-correlation 241 242 settings it had rMSEs of exactly zero. The reason for this is that pathway LASSO tended to be highly 243 conservative and successfully assigned inactive mediators to have no effect. As for the other methods, in 244 the baseline setting with 2,500 samples, MedFix performed the best when PVE_{IE} was 0.10, with a mean rMSE of 1.8x10⁻³ (CI: 1.9x10⁻⁴ - 6.4x10⁻³), which was 46% lower than the mean rMSE for the second-best 245 method, HIMA. In contrast, HIMA was the best-performing method when signal was weakened to a 246 PVE_{IE} of 0.05, attaining a mean rMSE of 2.8x10⁻⁴ (CI: 0.0 - 1.3x10⁻³), which was 94% lower than that of 247 the second-best, MedFix. Results were similar when the correlations between mediators were heightened 248 249 and when the sample size was reduced. In the settings where mediation signals were non-sparse, the best-



when PVE_{IE} was 0.10 and there were 2,500 observations, 2% lower than that of MedFix.





Fig. 5. MSE in estimating mediation contributions of inactive mediators, relative to one-at-a-time method.
Y-axis is on a log₁₀ scale. Value shown is the mean of the relative mean-squared error for estimating mediation
contributions among inactive mediators (relative to the one-at-a-time approach) across 100 simulated data replicates,
with intervals representing the inner 95% range. For baseline and high-correlation-between-mediators settings,
inactive mediators are those which do not contribute to the global mediation effect, whereas in the non-sparse
setting, inactive mediators are those whose contributions were sampled from a distribution with small variance
instead of large.

260

261 Estimation of global indirect effect

Lastly in Fig. 6, we show the percent relative bias for estimating $\alpha_a^{T}\beta_m$, the global indirect effect. 262 We use the same methods as in Figures 3 to 5 along with the Group 2 methods PCMA and HILMA, 263 which obtain an estimate of the global indirect effect without needing to directly fit the original mediation 264 265 model. (The Group 2 method SPCMA is excluded for computational reasons.) In the baseline setting with 2,500 samples, the best performer when PVE_{IE} was 0.10 was HILMA, whose mean relative bias of 9% 266 267 (CI: 0.6% - 20.8%) was 40% lower than that of HDMA, the second-best. Next, when the PVE was reduced to 0.05, the best-performing method was MedFix (mean relative bias: 20.5%; CI: 1.0% - 43.8%), 268 269 which outperformed HILMA by only 7%. We observed similar results for a sample size of 1,000 and high-correlations. In the non-sparse settings, where the biases tended to be much higher, the best

high-correlations. In the non-sparse settings, where the biases tended to be much hperforming methods were either PCMA or HDMA.





Fig. 6. Percent relative bias in estimated global indirect effect. Value shown is the mean of the percentage
 relative bias in estimating the global mediation effect across 100 simulated data replicates, with intervals
 representing the inner 95% range.

277

278 Scalability

- 279 We evaluated the scalability of the methods by running them 30 times on a common computing platform, and recording their run time (Table 1). This was done in both a small data setting (n = 100, p =280 200) and a big data setting (n = 1,000, p = 1,000). On the larger dataset, the methods MedFix, HDMA, 281 and PCMA posed insignificant computational burden; whereas BSLMM took an average of 40.1 minutes 282 per run (assuming 30,000 posterior samples), HILMA an average of 40.9 minutes per run, pathway 283 LASSO an average of 192.6 minutes per run, and SPCMA an average of 842.5 minutes per run (assuming 284 100 principal components). Run times were substantially lower in the smaller dataset, the slowest method, 285 pathway LASSO, only taking an average of 18.71 minutes. The memory consumption of the methods is 286 included in Supplementary Table 1. 287
- 288
- 289
- 290
- 291
- 292
- 293
- 294

295

296

297 Table 1. Computation time comparison for high-dimensional mediation analysis methods

	n = 1	.00, $p = 200$	n = 1,0	000, p = 2,000
Method	Mean	Interquartile Range	Mean	Interquartile Range
BSLMM	39.17s	(38.84s - 39.54s)	40.14m	(39.74m - 40.34m)
HDMA	1.40s	(1.37s - 1.40s)	29.76s	(29.55s - 29.92s)
HDMM	24.85s	(24.80s - 24.89s)	12.36m	(12.33m - 12.37m)
HILMA	24.42s	(24.13s - 24.63s)	40.85m	(38.22m - 40.65m)
HIMA	0.25s	(0.25s - 0.25s)	3.55s	(3.47s - 3.62s)
MEDFIX	0.61s	(0.60s - 0.61s)	7.33s	(7.22s - 7.42s)
PCMA	2.77s	(2.74s - 2.79s)	58.97s	(58.08s - 59.35s)
PLASSO	18.71m	(18.19m - 19.23m)	192.62m	(188.10m - 195.83m)
SPCMA	16.05m	(15.94m - 16.04m)	842.54m	(827.26m - 855.21m)

298

Methods were run 30 times each on a single core of an Intel(R) Xeon(R) Gold 6242R CPU @ 3.10GHz processor.

299

300 DNAm data analysis results from MESA

For our real data analysis, we applied the methods on a dataset with high-dimensional epigenetic 301 mediators. Our exposure of interest was low SES-measured by educational attainment below a four-year 302 303 degree—while our outcome variable was HbA1c level and our potential mediators were DNAm 304 measurements at 402,339 CpG sites. Since the methods are incapable of handling so many CpG sites at once, we reduced our scope to only include the 2,000 sites with the strongest association with low SES. 305 This was based on a linear mixed-model adjusting for age, sex, race, and the estimated proportions of 306 residual non-monocytes as fixed effects and methylation chip and position as random effects. Our final 307 dataset contained these 2,000 CpG sites and 963 samples. HbA1c, DNAm, and all other continuous 308 309 variables were standardized prior to analysis.

310

311 Identification of noteworthy CpG sites

We identified CpG sites that potentially mediated the relationship between low SES and HbA1c 312 using the Group 1 methods HIMA, HDMA, MedFix, pathway LASSO, and BSLMM. In HIMA, HDMA, 313 314 MedFix, and pathway LASSO, which involve feature selection, we describe a CpG site to be "active" if its estimated mediation contribution is not zero; whereas in BSLMM, we do so if the estimated posterior 315 316 inclusion probability is not zero (see Methods). We also included a one-at-a-time method in which the 317 CpG sites were assessed individually with linear mixed models, identifying active mediators with the joint significance test⁴⁴. Out of 2,000 CpG sites, HIMA found 3 sites to be noteworthy, HDMA found 11, 318 MedFix found 3, pathway LASSO found 141, and BSLMM found 3, amounting to 144 unique CpG sites 319 320 in total. The one-at-a-time method identified zero CpG sites as noteworthy at an FDR threshold of 10%. 321 Eleven CpG sites were identified as noteworthy by at least two of the methods (Table 2). Among these 322 11, the estimated mediation contributions were similar across methods in direction and size except for BSLMM, for which the estimates were an order of magnitude smaller than the others but in the same 323 324 direction.

- 325
- 326
- 327
- 328
- 329

- 330
- 331

332

Table 2. Estimated contributions of noteworthy CpG sites on the mediation pathway between low education and HbA1c

								Pathway	
			USCS	Univariate	HIMA	HDMA	MedFix	LASSO	BSLMM
		Nearby	RefGene	(0 sites	(3 sites	(11 sites	(3 sites	(141 sites	(3 sites
CpG Name	Chromosome	Gene(s)	Group	identified)	identified)	identified)	identified)	identified)	identified)
cg10508317	17	SOCS3	Body	3.48 x10 ⁻²	1.59 x10 ⁻² *	3.56 x10 ⁻² *	2.90 x10 ⁻² *	2.35 x10 ⁻² *	0.25 x10 ⁻²
cg01288337	14	RIN3	Body	3.35 x10 ⁻²	1.47 x10 ⁻² *	2.82 x10 ⁻² *	2.70 x10 ⁻² *	4.43 x10 ⁻² *	0.21 x10 ⁻²
cg10244976	16	LMF1	Body	3.00 x10 ⁻²	0	2.78 x10 ⁻² *	0	2.23 x10 ⁻² *	0.19 x10 ⁻²
cg07516252	14	REC8	TSS200	2.72 x10 ⁻²	0	2.24 x10 ⁻² *	0	2.26 x10 ⁻² *	0.26 x10 ⁻²
		C10orf105;							
cg07571519	10	CDH23	3'UTR; Body	2.53 x10 ⁻²	0.33 x10 ⁻² *	3.67 x10 ⁻² *	1.47x10 ⁻² *	2.81 x10 ⁻² *	0.21 x10 ⁻²
cg23079012	2	LINC00299	Body	2.27 x10 ⁻²	0	1.99 x10 ⁻² *	0	1.98 x10 ⁻² *	0.29 x10 ⁻²
cg01587454	8	DCAF4L2	1stExon	1.77 x10 ⁻²	0	2.10 x10 ⁻² *	0	1.99 x10 ⁻² *	0.38 x10 ⁻²
cg27527503	4	HADH	TSS1500	1.75 x10 ⁻²	0	1.86 x10 ⁻² *	0	1.27 x10 ⁻² *	0.23 x10 ⁻²
cg25891647	11	GRAMD1B	Body	-1.27 x10 ⁻²	0	-3.42 x10 ⁻² *	0	-3.02 x10 ⁻² *	-0.33 x10 ⁻²
cg08473752	17	NLK	Body	-0.70 x10 ⁻²	0	-2.34 x10 ⁻² *	0	-2.32 x10 ⁻² *	-0.22 x10 ⁻²
cg12644059	15	BLM	N/A^1	-0.03 x10 ⁻²	0	-2.31 x10 ⁻² *	0	-1.84 x10 ⁻² *	-0.22 x10 ⁻²

335 *Selected as noteworthy by given method

¹CpG site cg12644059 is 3.240kb from the final base pair of the BLM gene

337 Table includes all CpG sites that were selected as having a noteworthy mediation contribution by at least two of the

implemented methods out of 2,000 CpG sites in total. Criteria for CpG identification varied by method. All

estimates are adjusted for age, sex, race, and the estimated proportions of residual non-monocytes as fixed effects,

along with methylation chip and position as random effects to address potential batch effects. Note that for HIMA,

341 HDMA, MedFix, and pathway LASSO, which fit high-dimensional regression models, we used additional pre-

342 screening to reduce the number of mediators in advance to only $n/log(n) \approx 141$ CpG sites, which is the approach

343 recommended by the HIMA and HDMA authors and helps with statistical and computational efficiency (see

344 Methods). Pathway LASSO selected all of these 141.

345

346 Some of these CpG sites were on or nearby genes that are potentially related HbA1c. Site cg10508317 is in the body of the SOCS3 gene, for which a rich body of literature has established links 347 between overexpression and insulin resistance⁴⁵. The same site has also been identified in MESA as a 348 mediator between adult SES and BMI⁴⁶ and adult SES and HbA1c³¹ based on previous one-at-a-time 349 analyses. Site cg01288337, in the body of the RIN3 gene, has been identified in MESA as a potential 350 mediator between adult SES and HbA1c based on one-at-a-time analysis as well³¹. The *RIN3* gene itself is 351 proximal to the SLC24A4 gene, both of which have been linked to brain glucose metabolism in human 352 population studies⁴⁷. In addition, site cg27527503 is in the promoter region of the HADH gene, which is 353

differentially expressed with respect to diabetes status⁴⁸ and is a primary driver of hyperinsulinism⁴⁹ and

hyperinsulinaemic hypoglycemia (low blood sugar due to excess insulin)⁵⁰. A Venn diagram of genes
 identified by the methods is included in Supplementary Fig. 5, and results for every noteworthy CpG site

- are listed in Supplement File 1.
- 358

359 Global mediation through DNAm

Next, we estimated the direct effect of low education on HbA1c, the global indirect effect of loweducation on HbA1c through DNAm, and the total effect of low education on HbA1c using the Group 1

362 methods HIMA, HDMA, MedFix, pathway LASSO, and BSLMM, as well as the Group 2 methods

363 PCMA, SPCMA, and HILMA (Table 3). Results across methods varied considerably, with the estimated

364 global indirect effect ranging from 0.03 in HILMA to 0.17 in SPCMA. The estimated total effect ranged

from 0.02 (HILMA) to 0.198 (HIMA, HDMA, and MedFix). While HILMA appeared to be an outlier,

366 some of the other methods were consistent, with HDMA, BSLMM, P- LASSO, PCMA, and SPCMA all

367 estimating the global indirect effect to be close to 0.15. The variability in the estimated indirect effect and

368 estimated total effect led to variability in the proportion mediated as well, from 17.1% in HIMA to 100%

- in HILMA.
- 370

Estimated Total Estimated Direct Method Estimated Global **Estimated** Proportion Effect Effect indirect Effect Mediated 0.20 0.17 HIMA 0.03 0.16 0.13 0.20 0.65 HDMA 0.07 0.36 0.07 0.13 0.20 MedFix BSLMM 0.14 0.05 0.18 1.00 Pathway LASSO 0.13 0.05 0.18 0.74 PCMA 0.15 0.02 0.17 0.91 **SPCMA** 0.17 0.00 0.17 1.00 HILMA 0.03 0.00 0.03 1.00

371 Table 3. Estimated effects in the mediation mechanism from low education to DNAm to HbA1c

372 All estimates are adjusted for age, sex, race, and the estimated proportions of residual non-monocytes as fixed 373 effects, along with methylation chip and position as random effects to address potential batch effects. We provide 374 only point estimates, not interval estimates, because some of the methods are either not capable of producing 375 interval estimates or do not provide the code for producing them in their software. For HIMA, HDMA, and MedFix, 376 which as coded do not directly provide estimates of the direct effect, we first estimate the total effect by fitting the 377 outcome model with the CpG sites omitted, then estimate the direct effect by subtracting the indirect effect from the 378 total effect. Note also that, for HIMA, HDMA, MedFix, and pathway LASSO, we used additional screening to 379 reduce the number of mediators in advance for the sake of statistical and computational efficiency, so only n/log(n) 380 \approx 141 CpG sites were seen by the multivariate model rather than 2,000 (this approach is recommended by the HIMA

and HDMA authors).

382

383 Additional Findings

In addition to estimating the global indirect effect, method SPCMA is also able to identify potentially-mediating CpG sites in groups. It does so by linearly combining the mediators using sparse principal component-defined weights, then evaluating the resulting principal components as mediators themselves⁴⁰. However, out of 100 computed principal components, only three of them had significant mediation contributions after 10% FDR correction, the first representing a linear combination of 762 CpG sites, the second a combination of 782 sites, and the third a combination of 797 sites. Since the transformed mediators are functions of so many CpG sites at once, one cannot make claims about which

391 particular CpG sites are active mediators, but the method still provides insight to whether there is 392 statistical mediation at all.

We finish our analysis by deploying HDMM, a method from Group 3. Unlike the methods in Groups 1 and 2, HDMM cannot be used to estimate the global indirect effect from the proposed mediation

395 structure, nor to estimate the mediation contributions of specific CpG sites. Rather, HDMM uses a

396 likelihood-based approach to compute "directions of mediation", which are weights that can be used to

397 linearly combine the observed mediators into unobserved, latent mediators that replace the observed

398 mediators in the mediation models (similar to PCMA). The estimated effect of the first latent mediator on

average HbA1c was 0.13, the estimated total effect 0.71, and the proportion mediated 0.715. The three 399 400 CpG sites with the largest directions of mediation were cg01288337 (0.36) on the RIN3 gene,

cg16162970 (-0.22) near the PACS2 gene, and cg25891647 (-0.21) on the GRAMD1B gene; the first and 401 402 last of which were among the 11 CpG sites identified by other methods in Table 2. Although the size and

403 direction of these estimates are not interpretable, they offer evidence that these CpG sites are potentially

404 involved in mediation.

405

Discussion 406

407 In this study, we reviewed and evaluated statistical methods for performing mediation analysis with highdimensional DNAm data, so that researchers in epigenetics have the information they need to choose the 408

most appropriate method for their data sample, subject matter, and research objectives. In extensive 409

simulations, we found that the most powerful method for identifying active mediators was generally 410

BSLMM, with HDMA close behind; though the former performed poorly in settings where the mediation 411

412 signals were non-sparse. No method was uniformly better than the others at estimating the mediation

413 contributions, though pathway LASSO was always the weakest. For estimating the global indirect effect,

the best-performing method was HILMA in sparse mediation settings and PCMA or HDMA in non-414

sparse settings. Our scalability comparison revealed that HIMA, HDMA, MedFix, and PCMA were easily 415

scalable to large datasets (e.g., n = 1,000 and p = 2,000), whereas SPCMA and pathway LASSO were 416

extremely computationally costly. 417

On DNAm data from MESA, 11 CpG sites were selected by at least two of the methods as 418 mediators between low SES and HbA1c level. Of the many genes related to these sites, SOCS3, RIN3, 419 420 and HADH have the strongest potential biological connections to HbA1c^{45,47,48,50–52}, which contributes to the already rich literature on DNAm as a mediator between the exposome and health outcomes.

421

422 Moreover, the methods generally produced similar estimates of the mediation contributions, with the 423 exception of BSLMM. It is possible that since BSLMM is non-sparse, the estimated mediation

424 contributions end up severely shrunken compared to the methods which directly select features.

425 Estimates of the global indirect effect were highly variable. Part of this can be explained by the 426 fact that HDMA, MedFix, HIMA, and pathway LASSO are sparse models that can set mediation 427 contributions to be exactly zero, resulting in a rigid and unstable estimation of the global indirect effect. The method HILMA, which is built specifically for estimating the global indirect effect and direct effect, 428 429 produced estimates that were sharply different than the other methods, possibly because our simulations 430 indicated that it struggled in non-sparse mediation settings.

In practice, the optimal method for mediation analysis with high-dimensional mediators will 431 depend both on the data and the objective. If the goal is to identify specific CpG sites that are involved in 432 mediation, one preferred method may be HDMA, which performed well at detecting active mediators in 433 our simulations and was not overly conservative when applied to the observed data. If one's focus is the 434 global indirect effect, our simulations suggested that the optimal method is HILMA; but considering the 435 variability we observed in our DNAm analysis, it may be worthwhile to apply BSLMM and HDMA as 436 437 well to ensure the results are robust. If the results of multiple methods disagree substantially, it may be 438 difficult to say with confidence which is closest to the truth, and the estimates should be interpreted with caution. Next, if there is interest in latent, unmeasured mediators, either HDMM or LVMA is worth 439 440 attempting, though HDMM is computationally simpler. A detailed decision tree for selecting the optimal method is included in Fig. 7. 441

442





445 446

Fig. 7. Decision tree for selecting a high-dimensional mediation analysis.

447 Some strengths of our study include its broad coverage of the available methods, the breadth of 448 its simulation settings, and the comprehensive set of evaluation criteria. Our analysis of real DNAm data 449 is especially essential because it elucidates the potential limitations of using these methods in practice, as 450 it is impossible to incorporate the full complexity of real data sources into contrived simulation settings. 451 However, our study also has weaknesses. First, since DNAm measurements and HbA1c data were collected concurrently, and represent only single time points, we cannot interpret the parameters we have 452 estimated as causal effects. Nor can we interpret the mediation contributions estimated in Table (2) as 453 causal, since DNAm was correlated across CpG sites and we have made no assumptions about their 454 causal ordering. Moreover, although it would be optimal to address our research question longitudinally, 455 with measurements at multiple time points, there is a dearth of mediation analysis methods which can 456 handle that type of data, and longitudinal mediation analysis with high-dimensional mediators should be a 457 458 focus of future methodological development. Second, we limited our analysis to the situation that Y and 459 M are continuous, that M and A do not interact, and that only one A is of interest. However, we note that 460 the methods HIMA and HDMA can also be applied to identify active mediators when Y is binary, while PCMA can be applied to infer the global indirect effect when there is A-M interaction in the outcome 461 462 model. MedFix, along with the simultaneously-proposed MedMix (mediation analysis with mixed effect 463 model by Zhang (2021)) can be applied when both the exposures and mediators are high-dimensional,

464 while Huang and Vanderweele (2014) proposed a variance component test of the global indirect effect

465 when only A is high-dimensional⁵³. As the landscape of methods for high-dimensional mediation analysis

466 continues to expand, future review studies should consider exploring additional mediation settings (in

467 presence of non-linearity, interaction) for which statistical methods are continuing to become available.

468

469 Methods

and

470 Mediation Model with Multiple Mediators

471 Let M be a set of p variables, $M^{(1)}$, $M^{(2)}$, to $M^{(p)}$, each a potential mediator in the causal pathway between 472 A and Y. We assume that the ordering of the potential mediators is arbitrary and that Y is continuous. 473 Given a dataset of n individuals, with A_i , Y_i , M_i , and q covariates C_i measured for each subject i, we can 474 evaluate the mediating role of M with the models

$$E[Y_i|A_i, \boldsymbol{M}_i, \boldsymbol{C}_i] = \beta_a A_i + \boldsymbol{\beta}_m^T \boldsymbol{M}_i + \boldsymbol{\beta}_c^T \boldsymbol{C}_i$$
(1)

476 477

$$E[\boldsymbol{M}_i|A_i, \boldsymbol{C}_i] = \boldsymbol{\alpha}_{\boldsymbol{a}}A_i + \boldsymbol{\alpha}_{\boldsymbol{c}}\boldsymbol{C}_i.$$
(2)

We refer to these as the outcome and mediator models. Bolded terms distinguish vectors from 478 479 scalars. Under certain assumptions, the parameters of this model can be used to derive causal effects of interest: Namely, in addition to the baseline assumption of temporality, we assume (1) that there is no 480 481 unmeasured confounding in the exposure-outcome association after conditioning on C, (2) that there is no unmeasured confounding in the mediator-outcome associations after adjusting for the exposure and C, (3) 482 that there is no unmeasured confounding of the exposure-mediator associations after conditioning on C. 483 and (4) that the measured confounders of the mediator-outcome associations are not caused by the 484 exposure (which would make those confounders mediators themselves). In these circumstances only can 485 β_a be interpreted as the natural direct effect of A on Y, $\alpha_a^T \beta_m$ the natural indirect effect of A on Y through 486 M, and $\beta_a + \alpha_a^T \beta_m$ the total effect of A on Y^{33} . We say a mediator $M^{(j)}$ is *active* if $(\alpha_a)_j(\beta_m)_j$ is not zero, 487 since it contributes mathematically to the indirect effect, but this contribution itself cannot be formally 488 489 interpreted causally unless the mediators are independent conditional on A and C. Extensions of this framework cover cases when Y is binary, when M is binary, or when the outcome model requires an 490 interaction effect between M and A^{33} . 491

A summary of the methods that can evaluate *M* as a mediator is provided in Table 4, using the
above pair of models as a frame of reference. We describe each of the methods in greater detail in the
following three sections.

495

496 Table 4. Methods Summary.

Nama and	Estimation of	Estimation			
Author	indirect effect	contributions	Mediator identification	Y Data Type	Summary
Group 1 Methods	indirect effect	controutions		I Dutu Type	5 willing y
HIMA; Zhang, 2016	Point estimation	Point estimation	Yes	Continuous or binary	Fits the outcome model with the minimax concave penalty. Requires subsequent fitting of ordinary least squares regression to test the statistical significance the mediation contributions.
HDMA; Gao, 2019	Point estimation	Point, interval estimation	Yes	Continuous or binary	Fits the outcome model with the de-sparsified LASSO penalty.
MedFix; Zhang, 2021	Point estimation	Point, interval estimation	Yes	Continuous	Fits the outcome model with the adaptive LASSO penalty. Can also be applied when the exposure is high-dimensional in addition to the mediators.
Pathway LASSO Zhao and Luo, 2022	Point estimation	Point estimation	Yes	Continuous	Fits the outcome model and mediator models with a jointly penalized likelihood, directly applying shrinkage to the mediation contributions $(\alpha_a)_j(\beta_m)_j$.
BSLMM; Song, 2020	Bayesian point, interval estimation	Bayesian interval estimation	Yes	Continuous	Bayesian mixed-model in which the mediator-outcome associations $(\beta_m)_j$ and the exposure-mediator associations $(\alpha_a)_j$ are assumed to independently follow sparse normal distributions.
GMM; Song, 2021	Bayesian point, interval estimation	Bayesian interval estimation	Yes	Continuous	Bayesian mixed-model in which the mediator-outcome associations $(\beta_m)_j$ and the exposure-mediator associations $(\alpha_a)_j$ are assumed to jointly follow a sparse multivariate normal distribution.
Group 3 Methods				•	
PCMA; Huang and Pan, 2016	Point, interval estimation	No	No	Continuous or binary	Applies principal component analysis on the mediator model residuals, transforming the mediators so they are independent. Can be applied when there is A - M interaction in the outcome model.
SPCMA; Zhao, 2019	Point, interval estimation	No	Identifies whether subsets of the mediators are jointly active	Continuous	Similar to PCMA but applies sparse PCA, resulting in transformed mediators that are more interpretable.
HILMA; Zhou, 2020	Point, interval estimation	No	No	Continuous	Uses a debiased penalized regression approach to directly estimate the global indirect effect $\alpha_a^T \beta_m$. Can be applied for multiple exposures simultaneously.
Group 3 Methods	-	_			
HDMM; Chen, 2018	No	No	Nonspecifically identifies groups of active mediators	Continuous	Estimates "directions of mediation" by which the observed mediators can be linearly combined to form latent mediators. The latent mediators replace the true mediators in the analysis.
LVMA; Derkach, 2019	No	No	Identifies inputted mediators associated with latent mediators	Continuous or binary	Reformulates the causal structure of the mediation problem. Assumes that M itself is not responsible for mediation, but rather that the effect of A on Y is mediated by latent, unmeasured factors, F , which also cause changes in M .

498 **Group 1 Methods**

499 This group of methods can estimate both the global indirect effect $\alpha_a^T \beta_m$ and the mediator-specific

- 500 contributions $(\boldsymbol{\alpha}_a)_j (\boldsymbol{\beta}_m)_j$, *j* from 1 to *p*.
- 501

502 HIMA

503 High-dimensional mediation analysis (HIMA), proposed by Zhang et al. (2016), is a penalized regression

- approach with two main steps: First, the outcome model is fitted with a minimax concave penalty 54 ,
- performing feature selection on the mediators by setting some of them to have no effect on Y^{34} . Then,
- among the remaining mediators, they fit the mediator models individually using ordinary regression. The
- authors test the significance of $(\alpha_a)_i(\beta_m)_j$ by applying Bonferroni correction to the maximum of the $(\beta_m)_j$
- and $(\alpha_n)_j$ p-values. To obtain p-values for the $(\beta_m)_j$ estimates, the authors re-fit the reduced outcome model by ordinary least squares, which statistically may be overconfident. The authors also recommend
- an initial screening step to reduce the number of mediators at the start, as the outcome model will still be
- 511 unstable if *p* is extremely large compared to *n*.
- 512

513 HDMA

- High-dimensional mediation analysis (HDMA), proposed by Gao et al. (2019), is the same as HIMA
- 515 except for its penalty function, replacing the minimax concave penalty with the recently-proposed de-
- sparsified LASSO^{35,55}. The advantage of this penalty is that the resulting estimates of β_m are
- asymptotically normal, so one can test their statistical significance without needing to subsequently apply
- ordinary least squares. HDMA is also less biased than HIMA when the mediators are highly-correlated.
- 519

520 MedFix

- 521 Mediation analysis via fixed effect model (MedFix) is another extension of HIMA, proposed by Zhang
- $(2021)^{36}$. MedFix was originally proposed for a setting where there are not only multiple mediators, but
- also multiple exposures, which it handles by applying adaptive LASSO to both the outcome model and
- 524 the mediator models. If there is only one exposure, feature selection in the mediator models is not
- 525 necessary, and applying MedFix is analogous to applying HDMA except with adaptive LASSO instead of
- 526 debiased LASSO.
- 527

528 Pathway LASSO

- 529 Pathway LASSO is another penalized regression approach, proposed by Zhao and Luo (2022)³⁷. Whereas
- 530 HIMA, HDMA, and MedFix use a two-step design—the outcome model and mediator models fitted
- separately—this method fits the models all together, with a jointly penalized likelihood. The penalty not
- only applies shrinkage to the mediator-outcome associations, like the other methods, but also to the
- 533 exposure-mediator associations and the mediation contributions.
- 534

535 BSLMM

- 536 The Bayesian sparse linear mixed model (BSLMM) is a Bayesian approach proposed by Song et al.
- 537 $(2020)^{15}$. The model assumes α_n and β_m are random vectors, both independently following mixtures of
- normal distributions. Most of the effects are presumed to be small, owing to a normal distribution with
- 539 mean zero and small variance, while the others are allowed to be larger, resulting from a normal
- 540 distribution with higher variance. We estimate the effects with their posterior mean, and we distinguish

- 541 active mediators from inactive with their posterior inclusion probability of belonging to the distribution
- 542 with higher variance.
- 543
- 544 GMM
- 545 The Gaussian mixed model (GMM), proposed by Song et al. (2021), is an extension of BSLMM in which
- 546 the $(\alpha_a)_j$, $(\beta_m)_j$ pairs are treated as correlated, following a mixture of multivariate normal distributions
- 547 instead of two independent normal distributions⁴². Thus, GMM may be more useful than BSLMM if the
- 548 true size of each $(\beta_m)_j$ is related to the size of the corresponding $(\alpha_n)_j$, and vice-versa.
- 549

550 Group 2 Methods

- 551 This group of methods directly estimate the global indirect effect without producing estimates of its
- 552 mediator-specific contributions.
- 553

554 **PCMA**

- 555 Principal component mediation analysis (PCMA), proposed by Huan and Pan (2016), was an early
- 556 method for multiple-mediator mediation using principal component analysis (PCA)³⁹. The authors
- perform PCA on the residual matrix of the mediator models, then use the p by r loading matrix Q to
- transform the matrix M into a new set of mediators, M^* , which are uncorrelated conditional on A and C.
- 559 The transformed mediators then replace the original mediators in the analysis, and because they are
- uncorrelated, the outcome and mediator models can be fit without issue. Although the mediators have
- been transformed, and the mediator-specific contributions $(\alpha_a)_j(\beta_m)_j$ no longer correspond to the original
- 562 j^{th} mediator, the global indirect effect $\alpha_a^T \beta_m$ can still be estimated with its original interpretation. The
- authors set r to equal p, though this is only possible if p is less than n.
- 564

565 SPCMA

- 566 Zhao et al (2019) proposed sparse principal component analysis (SPCMA) to improve the interpretability
- 567 of the results from PCMA⁴⁰. In PCMA, the transformed mediators are difficult to interpret because they
- are sums of all p original mediators; whereas in SPCMA, the loading matrix Q is sparsified, meaning that
- seach transformed mediator is only a sum of a few of the original mediators. The results are easier to
- 570 interpret because, if a specific transformed mediator has a large effect, it can potentially be traced back to
- the original mediators which were used to construct it. SPCMA induces bias in its estimation compared to
- 572 PCMA, but it can be helpful for identifying groups of mediators which may be active.
- 573

574 HILMA

- 575 High-dimensional linear mediation analysis (HILMA), proposed by Zhou (2020), estimates $\alpha_a^T \beta_m$ with a
- 576 complex, de-biased penalized regression approach³⁸. The mathematics of the procedure are beyond the
- scope of this text, but the proposed estimator has asymptotic properties for testing whether $\alpha_a^T \beta_m$ is zero,
- and can also be applied when there are multiple (but not high-dimensional) exposures.
- 579

580 Group 3 Methods

- 581 The last group of methods is fundamentally distinct from the others: Instead of fitting the original
- mediation models (Group 1), or estimating the mediation effect without fitting the models (Group 2), they
- reconceptualize the causal structure of the problem to produce results with unique interpretations. Like

any method, they should only be applied when their assumptions about the causal structure arereasonable.

586

587 HDMM

588 High-dimensional multivariate mediation (HDMM), proposed by Chén et al. (2018), is similar to PCMA 589 in that it uses dimension reduction, but chooses the loading vectors with a likelihood-based approach 590 instead of PCA⁴¹. The loading vectors are referred to as "directions of mediation," each vector specifying a linear combination of mediators which contribute to the likelihood of the mediation models. Hence, 591 592 HDMM implicitly assumes that there are latent, unmeasured mediating variables that can be represented as linear combinations of the observed mediators. The results of HDMM are difficult to interpret, but it 593 594 can still be useful for identifying whether there is any mediation through M at all, and for identifying large subsets of mediators that contribute to that mediation. 595 596

597 LVMA

Latent variable mediation analysis (LVMA), proposed by Derkach et al. (2019), assumes that M itself is not involved in mediation, but rather, that there are a small number of unmeasured mediators, F, which transmit the effect of A to Y and which also cause changes in M^{43} . In other words, LVMA assumes explicitly what HDMM assumes implicitly, and the results of the two methods have a similar structure. A key feature of LVMA is that the $F \rightarrow M$ associations are sparsified, meaning that the method can be used for detecting relevant mediators in M. An observed mediator would be considered active if it is associated with a latent mediator that is itself associated with A and Y.

605

606 Simulation study

607 Simulation settings

608 We evaluate the above methods with a simulation study. To contrast them under diverse 609 conditions, we consider three different settings of mediation: (1) a baseline setting in which the mediation signals are sparse and the (potential) mediators are moderately correlated, (2) a high-correlation setting 610 with sparse signals, and (3) a moderate correlation setting in which the signals are non-sparse. Within 611 612 each of these settings, we also vary the degree of mediation by modifying three parameters: the proportion of variance in M that is explained by A among those associated with A (PVE_A), the proportion 613 of the variance of Y that is explained by the direct effect (PVE_{DF}), and the proportion of the variance of Y 614 that is explained by the global indirect effect (PVE_{IE}). For a baseline case, we let PVE_A equal 0.20 and 615 PVE_{DE} and PVE_{IE} both equal 0.10; then, in three additional cases, we sequentially decrease one of these 616 parameters by half, weakening the signal, and set the other two parameters to their values from the 617 baseline. Between Settings (1) to (3), this amounted to 12 unique data-generating mechanisms in total. 618 619 Each of these was evaluated with a sample size of 1,000 and 2,500, with the number of potential 620 mediators fixed at 2,000. All combinations of settings are listed below in Table 5. 621

- 622
- 623
- 624
- 625
- 626
- 627

628

629

630

Table 5. Complete list of settings in simulation study

Number of potential	Sample	Sparsity of	Degree of	PVEA	PVEIE	PVE _{DE}
mediators (p)	Size (<i>n</i>)	signals	correlation			
2000	2500	Sparse	Baseline	0.20	0.10	0.10
2000	2500	Sparse	Baseline	0.20	0.05	0.10
2000	2500	Sparse	Baseline	0.10	0.10	0.10
2000	2500	Sparse	Baseline	0.20	0.10	0.05
2000	2500	Sparse	High	0.20	0.10	0.10
2000	2500	Sparse	High	0.20	0.05	0.10
2000	2500	Sparse	High	0.10	0.10	0.10
2000	2500	Sparse	High	0.20	0.10	0.05
2000	2500	Non-sparse	Baseline	0.20	0.10	0.10
2000	2500	Non-sparse	Baseline	0.20	0.05	0.10
2000	2500	Non-sparse	Baseline	0.10	0.10	0.10
2000	2500	Non-sparse	Baseline	0.20	0.10	0.05
2000	1000	Sparse	Baseline	0.20	0.10	0.10
2000	1000	Sparse	Baseline	0.20	0.05	0.10
2000	1000	Sparse	Baseline	0.10	0.10	0.10
2000	1000	Sparse	Baseline	0.20	0.10	0.05
2000	1000	Sparse	High	0.20	0.10	0.10
2000	1000	Sparse	High	0.20	0.05	0.10
2000	1000	Sparse	High	0.10	0.10	0.10
2000	1000	Sparse	High	0.20	0.10	0.05
2000	1000	Non-sparse	Baseline	0.20	0.10	0.10
2000	1000	Non-sparse	Baseline	0.20	0.05	0.10
2000	1000	Non-sparse	Baseline	0.10	0.10	0.10
2000	1000	Non-sparse	Baseline	0.20	0.10	0.05

631 632

633 Simulated dataset creation

First, to obtain sparse mediation effects for Settings (1) and (2), we assume that 1,920 of the 634 2,000 coefficients (α_a) and (β_m) are zero and the remaining 80 are standard normal. Twenty of the 635 nonzero $(\alpha_a)_i$ and $(\beta_m)_i$ are chosen to overlap and have $(\alpha_a)_i(\beta_m)_i$ not equal to zero. To obtain non-sparse 636 signals for Setting (3), we sample the previously zero coefficients from a normal distribution with mean 637 638 zero and standard deviation 0.2. (These parameter vectors are sampled only once, at the start of the 639 simulations, so that the global mediation effect is held constant, but we shuffle the mediators in each dataset so that different mediators are assigned the effects each time.) Once we have these, we obtain a 640 single simulated dataset by sampling A_i from a standard normal distribution, then produce M_i from model 641 (4) assuming there are no covariates. We add noise to M_i by sampling residuals from a multivariate 642 643 normal distribution with mean $\mathbf{0}_{n}$ and variance $\boldsymbol{\Sigma}$, where $\boldsymbol{\Sigma}$ is derived by shuffling and then tuning the 644 variance-covariance of the observed methylation data (see supplementary section 1). In Settings (1) and (3), we tune Σ so that the correlations between mediators range from -0.37 to 0.49, and in Setting (2), so 645 that they range from -0.58 to 0.75. We fix PVE_A by scaling Σ appropriately based on α_a . Finally, we 646 define Y_i based on model (3) assuming the residuals are Normal($0,\sigma^2$), choosing β_a and σ^2 to yield the 647 648 desired PVE_{DE} and PVE_{IE}.

649

650 Evaluation

651 We evaluate the methods by applying them to 100 replicates of each setting in Table 5. We omit

- 652 SPCMA, GMM, and LVMA for computational reasons, as they are too computationally costly to deploy
- on so many replicates, and omit HDMM because it does not have an estimand that is comparable to the
- others. We include a one-at-a-time approach—in which the mediator are assessed individually using
- traditional mediation analysis and the joint significance test⁴⁴—as a baseline for comparison. When
- running HIMA, HDMA, MedFix, and pathway LASSO, we pre-screen the mediators to only include the
- 657 $n/\log(n)$ mediators with the strongest associations with Y adjusting for A, which is the approach
- recommended by the HIMA and HDMA authors^{34,35} (see supplementary section 2 for more details). For
- comparison metrics, we use (1) the true positive rate for detecting active mediators, TPR =
- 660 $\frac{\text{number of true mediators identified}}{\text{number of true mediators}}$; (2) the mean squared error in estimating the mediation contributions of
- 661 inactive mediators, $\text{MSE}_{\text{Inactive}} = \text{mean}_{j: \text{Inactive}} \left((\widehat{\boldsymbol{\alpha}_a})_j (\widehat{\boldsymbol{\beta}_m})_j (\boldsymbol{\alpha}_a)_j (\boldsymbol{\beta}_m)_j \right)^2$; (3) the mean squared
- 662 error in estimating the mediation contributions of active mediators, $MSE_{Active} =$
- 663 mean_{*j*: Active} $\left((\widehat{\alpha_a})_j (\widehat{\beta_m})_j (\alpha_a)_j (\beta_m)_j \right)^2$; and (4) the percent relative bias in estimating the global
- 664 indirect effect, $\frac{|\alpha_a^T \beta_m \alpha_a^T \beta_m|}{\alpha_a^T \beta_m} \times 100$. In the non-sparse setting, since all the mediators contribute to the 665 indirect effect, we consider the "active" ones to be those whose mediator-outcome and exposure-mediator
- 666 effects both come from the distribution with higher-variance, and the others inactive. Each metric is
 667 computed for each dataset to the applicable methods, and we report the average and a 95% empirical
 668 confidence interval over the 100 replicates.
- 669

670 Scalability comparison

671 We compare the scalability of the methods by assessing their processing time on simulated 672 datasets of two sizes: one with 100 observations and 200 mediators and one with 1,000 observations and 673 2,000 mediators. For the larger dataset, we use one of the datasets created for the simulation study, and 674 for the smaller dataset, we subset the rows and columns of M and the entries in A and Y. Run times are assessed on a single core of an Intel(R) Xeon(R) Gold 6242R CPU @ 3.10GHz processor. We attempt 675 each method 30 times and report the mean and interguartile range of the computation times. Since 676 SCPMA and BSLMM tend to be time-consuming, we approximate their run times by downscaling the 677 appropriate parameters: In particular, since the desired number of principal components in SPCMA is 678 679 100, we use only 2 principal components and scale the computing time by 50; and since the desired 680 number of posterior samples in BSLMM is 30,000, we draw only 750 samples and scale the result by 40. 681 Ad hoc experimentation confirmed that the methods were approximately linear with respect to these 682 inputs.

683

684 Data application with MESA

To demonstrate how these methods can be applied to observed DNAm data, we evaluate the association between SES and HbA1c and its potential mediation through DNAm. For the exposure, we use a binary variable that indicates low educational attainment (less than a 4-year college degree); for the outcome, we use HbA1c, a continuous variable that reflects average three-month blood glucose level. Our data for this portion come from the Multi-Ethnic Study of Atherosclerosis (MESA), a US populationbased longitudinal study¹⁷. Out of 6,814 total participants, a random subsample of 1,264 had their DNAm

691 measured at 484,882 CpG sites. We limit our analysis to the 963 participants who (1) had methylation 692 data, (2) had no missing data for the required variables, (3) consented to genetic and phenotypic use through the database of Genotypes and Phenotypes (dbGaP) (phs000209.v13.p3), and (4) were not on 693 diabetes medication, which can cause changes in HbA1c (Fig. 6). Standard quality control filters reduced 694 695 the number of CpG sites to 402.339. Since it is not statistically or computationally feasible to include so many mediators at once, we used a screening procedure to reduce that number further, fitting model (6) 696 below for each mediator separately to choose the 2,000 CpG sites at which DNAm was most strongly 697 associated with education based on the $(\alpha_a)_i$ p-value. These 2,000 formed the baseline set of CpGs for our 698 analysis. DNAm was measured using M-values, defined as the log-2 ratio of the methylated to 699 700 unmethylated probe intensities, which has the advantage of occurring on a continuous and unbounded 701 scale⁵⁶. For more details see supplementary section 3. A model for the proposed mechanism is given by $E[\text{HbA1c}_i|\text{Education}_i, \text{DNAm}_i, \text{Covariates}_i] = \beta_a \text{Education}_i + \beta_m^T \text{DNAm}_i + \beta_c^T \text{Covariates}_i$ (5) 702 703 and

 $E[\mathbf{DNAm}_i | \text{Education}_i, \mathbf{Covariates}_i] = \alpha_a \text{Education}_i + \alpha_c \mathbf{Covariates}_i$ 704 (6)where the covariates include age, sex, race, and the estimated proportions of residual non-monocytes (i.e., 705 706 neutrophils, B cells, T cells, and natural killer cells) as fixed effects and methylation chip and position as 707 random effects.



Fig. 6. Pre-processing of MESA methylation data. *Participants who consent to genetic and phenotypic data use, 708 709 and whose data is available on dbGaP.

710 We performed mediation analysis on the final dataset of 963 individuals and 2,000 CpG sites. All of the mediation methods described above were included except for GMM and LVMA, which again were too 711 costly computationally. Although it is reasonable for some of the methods to include all 2,000 CpG sites 712 directly in the multivariable model, HIMA and HDMA involve sure independence screening⁵⁷ to reduce 713 714 the number of mediators in advance to $n/\log(n)$, where n is the sample size. For the sake of consistency across the penalized regression methods, we do so with not only HIMA and HDMA, but also MedFix and 715 pathway LASSO, including only the 141 (963/log(963)) CpG sites most associated with low education (a 716 717 direct extension of the initial screening). (Note that, for HIMA and HDMA, this screening is part of the proposed method, not separate from it, but for MedFix and pathway LASSO the additional screening is 718 719 still beneficial for the sake of comparing methods and for statistical and computational efficiency). Additional pre-screening is not necessary for PCMA, SPCMA, BSLMM, and HILMA, and we include all 720 2,000 CpG sites directly; however, in HDMM, which cannot accommodate p > n simplistically, we again 721 use only twice-screened subset of 141 sites. For the sake of comparison with multivariate methods, we 722 also include a one-at-a-time mediation method based on linear regression and the joint significance test. 723 724 For estimating the total effect, the methods PCMA, SPCMA, BSLMM, and Pathway LASSO all produce 725 estimates of the direct effect, so we can estimate the total effect by summing the estimated direct and 726 global indirect effects. Since the methods HIMA, HDMA, and MedFix do not produce estimates of the direct effect, we first estimate the total effect on its own by fitting model (5) with the mediators excluded, 727 then subtract the estimated global indirect effect from this value to obtain an estimate of the direct effect. 728 729 As none of the high-dimensional methods are built to directly handle random effects as covariates, we 730 regress these out of the outcome variable and potential mediators in advance. For the fixed effect covariates, HIMA, HDMA, MedFix, and BSLMM allow one to include them directly; whereas in PCMA, 731 SPCMA, HILMA, HDMM, and pathway LASSO, we regressed them out in advance from the outcome 732 733 and mediators. Continuous variables (including HbA1c and the mediators) were standardized for all

- methods. All analysis was conducted using R version 4.2.1.
- 735

736 Data Availability

737 Data used for the simulation study are available from the authors upon request. Data used in the DNAm
738 analysis can be obtained through the MESA Data Coordinating Center (https://www.mesanhlbi.org/).

739

740 Code Availability

R scripts for the analysis are available at <u>https://github.com/dclarkboucher/mediation_DNAm</u>. Our R

- 742 package "hdmed" can be found at <u>https://github.com/dclarkboucher/hdmed</u>.
- 743

744 **References**

- Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 38, 23–38 (2013).
- 747 2. Kurdyukov, S. & Bullock, M. DNA Methylation Analysis: Choosing the Right Method. *Biology* (*Basel*). 5, (2016).
- 749 3. Dick, K. J. *et al.* DNA methylation and body-mass index: a genome-wide analysis. *Lancet* (*London, England*) 383, 1990–1998 (2014).
- 4. Wahl, S. *et al.* Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature* 541, 81–86 (2017).
- 5. Volkmar, M. et al. DNA methylation profiling identifies epigenetic dysregulation in pancreatic

754 islets from type 2 diabetic patients. EMBO J. 31, 1405–1426 (2012). 755 6. Chilunga, F. P. et al. Genome-wide DNA methylation analysis on C-reactive protein among 756 Ghanaians suggests molecular links to the emerging risk of cardiovascular diseases. NPJ genomic 757 *Med.* **6**, 46 (2021). Nakatochi, M. et al. Epigenome-wide association of myocardial infarction with DNA methylation 7. 758 759 sites at loci related to cardiovascular disease. Clin. Epigenetics 9, 54 (2017). 760 Fujii, R. *et al.* Dietary fish and ω -3 polyunsaturated fatty acids are associated with leukocyte 8. ABCA1 DNA methylation levels. Nutrition 81, 110951 (2021). 761 Sun, Y. V et al. Epigenomic association analysis identifies smoking-related DNA methylation 762 9. 763 sites in African Americans. Hum. Genet. 132, 1027–1037 (2013). Philibert, R. A., Plume, J. M., Gibbons, F. X., Brody, G. H. & Beach, S. R. H. The impact of 764 10. 765 recent alcohol use on genome wide DNA methylation signatures. Front. Genet. 3, 54 (2012). 766 11. Rider, C. F. & Carlsten, C. Air pollution and DNA methylation: effects of exposure in humans. 767 *Clin. Epigenetics* **11**, 131 (2019). Lam, L. L. et al. Factors underlying variable DNA methylation in a human community cohort. 768 12. 769 Proc. Natl. Acad. Sci. U. S. A. 109 Suppl, 17253–17260 (2012). Needham, B. L. et al. Life course socioeconomic status and DNA methylation in genes related to 770 13. 771 stress reactivity and inflammation: The multi-ethnic study of atherosclerosis. *Epigenetics* 10, 958-969 (2015). 772 773 14. Fujii, R., Sato, S., Tsuboi, Y., Cardenas, A. & Suzuki, K. DNA methylation as a mediator of 774 associations between the environment and chronic diseases: A scoping review on application of mediation analysis. *Epigenetics* 1–27 (2021) doi:10.1080/15592294.2021.1959736. 775 776 15. Song, Y. et al. Bayesian shrinkage estimation of high dimensional causal mediation effects in 777 omics studies. Biometrics 76, 700-710 (2020). 778 16. Du, J. et al. Methods for Large-scale Single Mediator Hypothesis Testing: Possible Choices and 779 Comparisons. (2022) doi:10.48550/arxiv.2203.13293. 780 17. Bild, D. E. et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am. J. Epidemiol. 781 156, 871-881 (2002). 782 18. Whitaker, S. M. et al. The Association Between Educational Attainment and Diabetes Among Men in the United States. American journal of men's health vol. 8 (2014). 783 784 19. Sakurai, M. et al. HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population: NIPPON DATA90. Diabetes Care 36, 3759–3765 (2013). 785 786 20. Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W. & Evans, J. C. Association of 787 HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart 788 Study. Diabetes 41, 202–208 (1992). 789 21. Yeung, S. L. A., Luo, S. & Schooling, C. M. The Impact of Glycated Hemoglobin (HbA(1c)) on 790 Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank. Diabetes Care 41, 1991–1997 (2018). 791 792 22. Borghol, N. et al. Associations with early-life socio-economic position in adult DNA methylation. 793 Int. J. Epidemiol. 41, 62–74 (2012). 794 23. Chen, Z. et al. DNA methylation mediates development of HbA1c-associated complications in 795 type 1 diabetes. Nat. Metab. 2, 744-762 (2020). 796 Baron, R. M. & Kenny, D. A. The Moderator-Mediator Variable Distinction in Social 24. 797 Psychological Research: Conceptual, Strategic, and Statistical Considerations. Journal of personality and social psychology vol. 51. 798 799 MacKinnon, D. Introduction to statistical mediation analysis. (New York, NY u.a: Erlbaum). 25. 800 26. VanderWeele, T. J. Marginal Structural Models for the Estimation of Direct and Indirect Effects. *Epidemiology* **20**, (2009). 801 27. 802 Pearl, J. Direct and Indirect Effects. in Proceedings of the Seventeenth Conference on Uncertainty in Artificial Intelligence 411-420 (Morgan Kaufmann Publishers Inc., 2001). 803 Robins, J. M. & Greenland, S. Identifiability and exchangeability for direct and indirect effects. 804 28.

805		<i>Epidemiology</i> 3 , 143–155 (1992).
806	29.	VanderWeele, T. J. Mediation Analysis: A Practitioner's Guide. Annu. Rev. Public Health 37, 17–
807		32 (2016).
808	30.	VanderWeele author., T. <i>Explanation in causal inference: methods for mediation and interaction</i> .
809		Explanation in causal inference: methods for mediation and interaction (Oxford University Press,
810		2015).
811	31.	Du, J. et al. Methods for large-scale single mediator hypothesis testing: Possible choices and
812		comparisons. Genet. Epidemiol. n/a, (2022).
813	32.	Aung, M. T. et al. Application of an analytical framework for multivariate mediation analysis of
814		environmental data. Nat. Commun. 11, 5624 (2020).
815	33.	VanderWeele, T. J. & Vansteelandt, S. Mediation Analysis with Multiple Mediators. <i>Epidemiol.</i>
816		<i>Method.</i> 2 , 95–115 (2014).
817	34.	Zhang, H. et al. Estimating and testing high-dimensional mediation effects in epigenetic studies.
818		<i>Bioinformatics</i> 32 , 3150–3154 (2016).
819	35.	Gao, Y. et al. Testing Mediation Effects in High-Dimensional Epigenetic Studies. Front. Genet.
820		10 , 1195 (2019).
821	36.	Zhang, Q. High-Dimensional Mediation Analysis with Applications to Causal Gene Identification.
822		Statistics in biosciences (2021).
823	37.	Zhao, Y. & Luo, X. Pathway LASSO: pathway estimation and selection with high-dimensional
824		mediators. Stat. Interface 15, 39–50 (2022).
825	38.	Zhou, R. R., Wang, L. & Zhao, S. D. Estimation and inference for the indirect effect in high-
826		dimensional linear mediation models. Biometrika 107, 573-589 (2020).
827	39.	Huang, YT. & Pan, WC. Hypothesis test of mediation effect in causal mediation model with
828		high-dimensional continuous mediators. Biometrics 72, 402–413 (2016).
829	40.	Zhao, Y., Lindquist, M. A. & Caffo, B. S. Sparse principal component based high-dimensional
830		mediation analysis. Comput. Stat. Data Anal. 142, 106835 (2020).
831	41.	Chén, O. Y. et al. High-dimensional multivariate mediation with application to neuroimaging data.
832		Biostatistics (Oxford, England) vol. 19 (2018).
833	42.	Song, Y. et al. Bayesian sparse mediation analysis with targeted penalization of natural indirect
834		effects. J. R. Stat. Soc. Ser. C (Applied Stat. 70, 1391–1412 (2021).
835	43.	Derkach, A., Pfeiffer, R. M., Chen, TH. & Sampson, J. N. High dimensional mediation analysis
836		with latent variables. Biometrics 75, 745–756 (2019).
837	44.	MacKinnon, D. P., Lockwood, C. M., Hoffman, J. M., West, S. G. & Sheets, V. A comparison of
838		methods to test mediation and other intervening variable effects. <i>Psychol. Methods</i> 7, 83–104
839		(2002).
840	45.	Pedroso, J. A. B., Ramos-Lobo, A. M. & Donato, J. J. SOCS3 as a future target to treat metabolic
841		disorders. Hormones (Athens). 18, 127–136 (2019).
842	46.	Wang, Y. Z. et al. DNA Methylation Mediates the Association Between Individual and
843		Neighborhood Social Disadvantage and Cardiovascular Risk Factors. Front. Cardiovasc. Med. 9,
844		848768 (2022).
845	47.	Stage, E. et al. The effect of the top 20 Alzheimer disease risk genes on gray-matter density and
846		FDG PET brain metabolism. Alzheimer's Dement. (Amsterdam, Netherlands) 5, 53–66 (2016).
847	48.	Mei, H. et al. Tissue Non-Specific Genes and Pathways Associated with Diabetes: An Expression
848		Meta-Analysis. Genes (Basel). 8, (2017).
849	49.	Rahman, S. A., Nessa, A. & Hussain, K. Molecular mechanisms of congenital hyperinsulinism. J.
850		<i>Mol. Endocrinol.</i> 54 , R119–R129 (2015).
851	50.	Galcheva, S., Al-Khawaga, S. & Hussain, K. Diagnosis and management of hyperinsulinaemic
852		hypoglycaemia. Best Pract. Res. Clin. Endocrinol. Metab. 32, 551–573 (2018).
853	51.	Pedroso, J. A. B. et al. Inactivation of SOCS3 in leptin receptor-expressing cells protects mice
854		from diet-induced insulin resistance but does not prevent obesity. Mol. Metab. 3, 608–618 (2014).
855	52.	Senniappan, S., Shanti, B., James, C. & Hussain, K. Hyperinsulinaemic hypoglycaemia: genetic

856	mechanisms, diagno	osis and management. J	. Inherit. Metab. L	Dis. 35, 589–601 (2012).
-----	--------------------	------------------------	---------------------	--------------------	--------

- 53. Huang, Y.-T., Vanderweele, T. J. & Lin, X. Joint analysis of SNP and gene expression data in genetic association studies of complex diseases. *Ann. Appl. Stat.* 8, 352–376 (2014).
- S59 54. Zhang, C.-H. Nearly unbiased variable selection under minimax concave penalty. *Ann. Stat.* 38, 894–942 (2010).
- Solution Statistical Society. Series B, Statistical Methodology vol. 76 (2014).
 Solution Statistical Society. Series B, Statistical Socie
- 56. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying methylation levels
 by microarray analysis. *BMC Bioinformatics* 11, 587 (2010).
- Fan, J. & Lv, J. Sure independence screening for ultrahigh dimensional feature space. J. R. Stat.
 Soc. 70, 849–911 (2008).
- 868

869 Acknowledgements

- 870 MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and
- 871 Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by
- 872 contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-
- 873 95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-
- HC 95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC- 95166,
- 875 N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420,
- UL1-TR-001881, and DK063491. The MESA Epigenomics & Transcriptomics Studies were funded by
- 877 NIH grants 1R01HL101250, 1RF1AG054474, R01HL126477, R01DK101921,
- and R01HL135009. Co-authors of this manuscripts were partially supported by NHLBI grant
- 879 R01HL141292, NSF grant DMS1712933, and NIH grants R01HG008773 and 1UG3CA267907.